妊娠期糖尿病应用诺和锐30R与诺和灵30R治疗疗效及优越性对照分析  

Contrast Analysis the Efficacy and Superiority of Insulin Aspart 30R and Novolin 30R on Gestational Diabetes Patients

作　　者：黄宏超 茹仲轩 李阳 HUANG Hong-chao RU Zhong-xuan LI Yang.(Shunde Maternity and Child Care Hospital, Foshan 528300, Chin)

机构地区：[1]广东省佛山市顺德区妇幼保健院,广东佛山528300

出　　处：《中国医学创新》2017年第19期124-126,共3页Medical Innovation of China

摘　　要：目的:研究分析妊娠期糖尿病应用诺和锐30R与诺和灵30R治疗疗效及优越性。方法:选取本院2014年5月-2016年5月妊娠期糖尿病患者80例,按照随机数字表法将其分为对照组与观察组,每组各40例。对照组采用诺和灵30R治疗,观察组采用诺和锐30R治疗,比较分析两组治疗疗效及优越性。结果:治疗后观察组HOMA-β、HOMA-IR、空腹血糖、餐后血糖等指标明显优于对照组,差异均有统计学意义(P<0.05)。观察组总有效率为92.5%,明显优于对照组77.5%,比较差异有统计学意义(P<0.05)。结论:妊娠期糖尿病患者分别采用诺和锐30R和诺和灵30R治疗后,前者疗效更为显著,能明显减少由于血糖升高而给患者产生的不良影响,还能增强患者药物治疗的有效性,值得临床推广。Objective： To study and analyze the efficacy and superiority of Insulin aspart 30R and Novolin 30R on gestational diabetes patients.Method： From May 2014 to May 2016 in our hospital, 80 cases of gestational diabetes were selected as the study objects and were divided into the control group and the observation group according to random number table method, 40 cases in each group.The control group was treated with Novolin 3OR, the observation group was treated with Insulin aspart 3OR.Curative effect and superiority of two groups were compared.Result： After the treatment, HOMA-β , HOMA-IR, fasting blood glucose, postprandial blood glucose of the observation group were obviously better than those of the control group, the differences were statistically significant （ P〈0.05 ） .The total effective rate of the observation group was 92.5% significantly better than the control group of 77.5%, the difference was statistically significant （P〈0.05） .Conclusion： Compared with Novolin 30R, the curative effect of Insulin aspart 30R is more significant for gestational diabetes.Insulin aspart 30R can not only significantly decrease adverse effects of elevated glucose levels, but also enhance the effectiveness of drug treatment to the patients, so it is worthy of clinical application and promotion.

关 键 词：妊娠期糖尿病 诺和锐 诺和灵30R 疗效 优越性 

分 类 号：R714.256[医药卫生—妇产科学]